Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD.



We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for treatment withdrawal in CD patients. We performed a retrospective, single-center cohort study of CD patients treated with IFX or ADA for at least 6 months between June 2002 and May 2016.



The median duration of follow-up was 5.4 years. For first-line anti-TNF agent, data on 487 patients with CD were analyzed. The mean (SD) duration of persistence was 3.6 (3.1) years and 2.5 (2.0) years in the IFX and ADA subgroups, respectively; the intergroup difference was not significant (P = 0.219). Factors associated with lower persistence were female sex (P = 0.0005) and stricturing behavior (P = 0.008). For second-line anti-TNF agent, data on 134 patients were analyzed. The mean (SD) duration of persistence was 2.4 (1.9) years and 2.6 (2.1) years in the IFX and ADA subgroups, respectively; again, the intergroup difference was not significant (P = 0.488). Age under 37.2 was the only factor associated with lower persistence (P = 0.016) for second-line treatment with an anti-TNF agent.



IFX and ADA show similar levels of persistence as first- and second-line anti-TNF treatments. Female sex and stricturing behavior were associated with poor persistence of first-line treatments, whereas age was the only factor associated with poor persistence of second-line treatments.
*INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre-lès-Nancy, France; †ESPRI-BioBase Unit, PARC Clinical Research Support Facility, Nancy University Hospital, Nancy, France; and ‡Humanitas University, IBD Center, Milan, Italy.
Pablo
P
Olivera
Linda
L
Thiriet
Amandine
A
Luc
Cedric
C
Baumann
Silvio
S
Danese
Laurent
L
Peyrin-Biroulet
D000068879:Adalimumab / Q000008:administration & dosage*; D000328:Adult; D000068582:Certolizumab Pegol / Q000008:administration & dosage; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage*; D008297:Male; D015999:Multivariate Analysis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult; D016903:Drug Monitoring
D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol